223,194 Shares in Haleon PLC Sponsored ADR $HLN Bought by Arlington Partners LLC

Key Points

• Arlington Partners LLC has acquired a new stake in Haleon PLC, purchasing 223,194 shares valued at approximately $2.3 million.
• BNP Paribas upgraded Haleon's stock to a "strong-buy" rating, while other analysts have mixed views, leading to an average rating of "Moderate Buy" with a price target of $12.33.
• Haleon recently increased its semi-annual dividend to $0.0555 per share, representing a dividend yield of 190.0%, up from the previous amount of $0.05.

Arlington Partners LLC purchased a new stake in shares of Haleon PLC Sponsored ADR (NYSE:HLN - Free Report) in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund purchased 223,194 shares of the company's stock, valued at approximately $2,315,000.

A number of other large investors have also recently made changes to their positions in the stock. Brighton Jones LLC purchased a new position in Haleon in the 4th quarter worth approximately $187,000. Ameriprise Financial Inc. raised its holdings in shares of Haleon by 15.8% during the 4th quarter. Ameriprise Financial Inc. now owns 120,122 shares of the company's stock worth $1,146,000 after acquiring an additional 16,429 shares in the last quarter. Millennium Management LLC raised its holdings in shares of Haleon by 82.5% during the 4th quarter. Millennium Management LLC now owns 528,891 shares of the company's stock worth $5,046,000 after acquiring an additional 239,019 shares in the last quarter. Two Sigma Advisers LP purchased a new stake in shares of Haleon during the 4th quarter worth approximately $2,391,000. Finally, Vident Advisory LLC raised its holdings in shares of Haleon by 99.3% during the 4th quarter. Vident Advisory LLC now owns 67,066 shares of the company's stock worth $640,000 after acquiring an additional 33,415 shares in the last quarter. 6.67% of the stock is owned by hedge funds and other institutional investors.

Haleon Stock Down 1.6%

Shares of HLN traded down $0.15 during midday trading on Monday, reaching $9.02. 9,766,140 shares of the stock were exchanged, compared to its average volume of 8,421,567. The company has a current ratio of 0.87, a quick ratio of 0.63 and a debt-to-equity ratio of 0.48. The company has a market capitalization of $40.35 billion, a P/E ratio of 23.12, a PEG ratio of 2.71 and a beta of 0.23. Haleon PLC Sponsored ADR has a 52 week low of $8.86 and a 52 week high of $11.42. The company's 50 day moving average is $9.64 and its two-hundred day moving average is $10.15.

Haleon Increases Dividend

The business also recently disclosed a semi-annual dividend, which was paid on Thursday, September 18th. Investors of record on Friday, August 15th were paid a dividend of $0.0555 per share. This is an increase from Haleon's previous semi-annual dividend of $0.05. The ex-dividend date was Friday, August 15th. This represents a dividend yield of 190.0%. Haleon's dividend payout ratio (DPR) is currently 28.21%.

Analysts Set New Price Targets

Several equities analysts have recently weighed in on the company. BNP Paribas raised Haleon to a "strong-buy" rating in a research report on Tuesday, May 27th. BNP Paribas Exane raised Haleon from a "neutral" rating to an "outperform" rating and set a $13.40 target price on the stock in a research report on Tuesday, May 27th. Wall Street Zen downgraded Haleon from a "buy" rating to a "hold" rating in a research report on Saturday, July 12th. Barclays downgraded Haleon from an "overweight" rating to an "equal weight" rating in a research report on Tuesday, September 16th. Finally, The Goldman Sachs Group raised Haleon from a "neutral" rating to a "buy" rating in a research report on Wednesday, September 10th. Two analysts have rated the stock with a Strong Buy rating, three have issued a Buy rating and five have given a Hold rating to the stock. Based on data from MarketBeat, Haleon has a consensus rating of "Moderate Buy" and a consensus price target of $12.33.

Haleon Profile

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.